Telix - 6K for ProstACT Global Phase 3

6-K 1 telix-6kforprostactglobalp.htm 6-K Telix - 6K for ProstACT Global Phase 3

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2026

Commission File Number: 001-42128

Telix Pharmaceuticals Limited

(Translation of registrant’s name into English)

55 Flemington Road

North Melbourne, Victoria 3051, Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On July 2, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed an announcement with the Australian

Securities Exchange titled “FDA Alignment to Advance ProstACT Global Phase 3 Trial,” a copy of which is

attached to this Form 6-K as Exhibit 99.1.

The information contained in this Form 6-K, except for (i) the commentary in Exhibit 99.1 appearing in the third and

fourth paragraphs on page 1 and (ii) information accessible by hyperlinks included therein, is incorporated by

reference into our Registration Statement on Form F-3ASR (File No. 333-293611) and Registration Statement on

Form S-8 (File No. 333-283917).


99.1	Press release – July 2, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be

signed on its behalf by the undersigned, thereunto duly authorized.



		Telix Pharmaceuticals Limited

Date:	July 2, 2026	By:	/s/ Christian Krautkramer
			Name: Christian Krautkramer
			Title: Group General Counsel